MZ1 co-operates with trastuzumab in HER2 positive breast cancer

BACKGROUND: Although the anti-HER2 antibody trastuzumab augments patient survival in HER2+ breast cancer, a relevant number of patients progress to this treatment. In this context, novel drug combinations are needed to increase its antitumor activity. In this work, we have evaluated the efficacy of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Exp Clin Cancer Res
Hlavní autoři: Noblejas-López, María del Mar, Nieto-Jiménez, Cristina, Galán-Moya, Eva M., Tebar-García, David, Montero, Juan Carlos, Pandiella, Atanasio, Burgos, Miguel, Ocaña, Alberto
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2021
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7980639/
https://ncbi.nlm.nih.gov/pubmed/33741018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-021-01907-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky